| [1] |
Kroman N, Jensen MB, Wohlfahrt J, et al. Factors influencing the effect of age on prognosis in breast cancer:population based study[J]. BMJ,2000,320(7233):474-478.
|
| [2] |
Han W, Kang SY, Korean Breast Cancer Society. Relationship between age at diagnosis and outcome of premenopausal breast cancer: age less than 35 years is a reasonable cut-off for defining young age-onset breast cancer[J]. Breast Cancer Res Treat,2010,119(1):193-200.
|
| [3] |
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013[J]. CA Cancer J Clin,2013,63(1):11-30.
|
| [4] |
Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review,1975-2009 (vintage 2009 populations), National Cancer Institute[EB/OL]. [2012-12-05]. http:/ /seer.cancer.gov/csr/1975_2009_pops09/.
|
| [5] |
Yang HJ, Yu XF, He XM, et al. Age interactions in breast cancer: an analysis of a 10-year multicentre study in China[J]. J Int Med Res,2012,40(3):1130-1140.
|
| [6] |
张保宁. 乳腺癌保乳手术的年龄与切缘[J/CD]. 中华普通外科学文献:电子版,2009,3(4):265-266.
|
| [7] |
Oh JL, Bonnen M,Outlaw ED,et al. The impact of young age on locoregional recurrence after doxorubicin-based breast conservation therapy in patients 40 years old or younger: How young is “young”? [J]. Int J Radiat Oncol Biol Phys,2006,65(5):1345-1352.
|
| [8] |
Cancello G, Maisonneuve P, Rotmensz N,et al. Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (＜35 years) with operable breast cancer[J]. Ann Oncol,2010,21(10):1974-1981.
|
| [9] |
Sidoni A, Cavaliere A, Bellezza G, et al. Breast cancer in young women: clinicopathological features and biological specificity[J]. Breast,2003,12(4):247-250.
|
| [10] |
Xiong Q, Valero V, Kau V, et al. Female patients with breast carcinoma age 30 years and younger have a poor prognosis: the M.D. Anderson Cancer Center experience[J]. Cancer,2001,92(10):2523-2528.
|
| [11] |
Gajdos C, Tartter PI, Bleiweiss IJ, et al. Stage 0 to stage Ⅲbreast cancer in young women[J]. J Am Coll Surg, 2000,190(5): 523-529.
|
| [12] |
Lin CH, Lu YS, Huang CS, et al. Prognostic molecular markers in women aged 35 years or younger with breast cancer:is there a difference from the older patients? [J]. J Clin Pathol,2011,64(9):781-787.
|
| [13] |
Kerlikowske K. Epidemiology of ductal carcinoma in situ[J]. J Natl Cancer Inst Monogr,2010,2010(41):139-141.
|
| [14] |
Jmor S, Al-Sayer H, Heys SD, et al. Breast cancer in women aged 35 and under: prognosis and survival[J]. J R Coll Surg Edinb,2002,47(5):693-699.
|
| [15] |
Morrison DH, Rahardja D, King E, et al. Tumour biomarker expression relative to age and molecular subtypes of invasive breast cancer[J]. Br J Cancer,2012,107(2):382-387.
|
| [16] |
Anders CK, Hsu DS, Broadwater G, et al. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression[J]. J Clin Oncol,2008,26(20):3324-3330.
|
| [17] |
Carvalho FM, Bacchi LM, Santos PP, et al. Triple-negative breast carcinomas are a heterogeneous entity that differs between young and old patients[J]. Clinics (Sao Paulo),2010,65(10):1033-1036.
|
| [18] |
Bacchi LM, Corpa M, Santos PP, et al. Estrogen receptorpositive breast carcinomas in younger women are different from those of older women: a pathological and immunohistochemical study[J]. Breast,2010,19(2):137-141.
|
| [19] |
Anders CK,Fan C,Parker JS,et al. Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes? [J]. J Clin Oncol,2011,29(1): e18-20.
|
| [20] |
Karlsson P, Cole BF, Price KN, et al. The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer[J]. J Clin Oncol,2007,25(15):2019-2026.
|
| [21] |
Chen W, Pan K, Ouyang T, et al. BRCA1 germline mutations and tumor characteristics in Chinese women with familial or early-onset breast cancer[J]. Breast Cancer Res Treat, 2009,117(1):55-60.
|
| [22] |
Samphao S, Wheeler AJ, Rafferty E, et al. Diagnosis of breast cancer in women age 40 and younger: delays in diagnosis result from underuse of genetic testing and breast imaging[J]. Am J Surg,2009,198(4):538-543.
|
| [23] |
Voogd AC, Nielsen M, Peterse JL, et al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage Ⅰand Ⅱbreast cancer:pooled results of two large European randomized trials[J]. J Clin Oncol,2001,19(6):1688-1697.
|
| [24] |
Bharat A, Aft RL, Gao F, et al. Patient and tumor characteristics associated with increased mortality in young women (＜or=40 years) with breast cancer[J]. J Surg Oncol,2009,100(3):248-251.
|
| [25] |
Roder DM, de Silva P, Zorbas HM, et al. Age effects on survival from early breast cancer in clinical settings in Australia[J]. ANZ J Surg,2012,82(7/8):524-528.
|
| [26] |
Foulkes WD. Inherited susceptibility to common cancers[J]. N Engl J Med,2008,359(20):2143-2153.
|
| [27] |
Armes JE, Trute L, White D, et al. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study [ J].Cancer Res,1999,59(8):2011-2017.
|
| [28] |
No authors listed. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group[J]. Br J Cancer,2000,83(10):1301-1308.
|
| [29] |
Malone KE, Daling JR, Neal C, et al. Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases[J]. Cancer,2000,88(6):1393-1402.
|
| [30] |
Peto J, Collins N, Barfoot R, et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer[J]. J Natl Cancer Inst,1999,91(11):943-949.
|
| [31] |
Son BH, Ahn SH, Kim SW, et al. Prevalence of BRCA1 and BRCA2 mutations in non-familial breast cancer patients with high risks in Korea: the Korean Hereditary Breast Cancer(KOHBRA) Study[J]. Breast Cancer Res Treat,2012,133(3):1143-1152.
|
| [32] |
Zhang J,Pei R,Pang Z, et al. Prevalence and characterization of BRCA1 and BRCA2 germline mutations in Chinese women with familial breast cancer[J]. Breast Cancer Res Treat,2012,132(2):421-428.
|
| [33] |
Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance[J]. J Clin Oncol,2007,25(11):1329-1333.
|
| [34] |
Nixon AJ, Neuberg D, Hayes DF, et al. Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage Ⅰor Ⅱbreast cancer[J]. J Clin Oncol,1994,12(5):888-894.
|
| [35] |
Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer[J]. N Engl J Med,2002,347(16):1227-1232.
|
| [36] |
Arriagada R, Lê MG, Guinebretière JM, et al. Late local recurrences in a randomised trial comparing conservative treatment with total mastectomy in early breast cancer patients[J]. Ann Oncol,2003,14(11):1617-1622.
|
| [37] |
de Bock GH, van der Hage JA, Putter H, et al. Isolated locoregional recurrence of breast cancer is more common in young patients and following breast conserving therapy: long-term results of European Organisation for Research and Treatment of Cancer studies[J]. Eur J Cancer,2006,42(3):351-356.
|
| [38] |
Hunt KK, Ballman KV, McCall LM, et al. Factors associated with local-regional recurrence after a negative sentinel node dissection: results of the ACOSOG Z0010 trial[J]. Ann Surg,2012,256(3):428-436.
|
| [39] |
Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials[J]. Lancet,2005,366(9503):2087-2106.
|
| [40] |
Johnson RH, Chien FL, Bleyer A. Incidence of breast cancer with distant involvement among women in the United States,1976 to 2009[J]. JAMA,2013,309(8):800-805.
|
| [41] |
Rubino C, Arriagada R, Delaloge S, et al. Relation of risk of contralateral breast cancer to the interval since the first primary tumour[J]. Br J Cancer,2010,102(1):213-219.
|
| [42] |
Ahn SH, Son BH, Kim SW, et al. Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea--a report from the Korean Breast Cancer Society[J]. J Clin Oncol,2007,25(17):2360-2368.
|
| [43] |
陈永胜, 朱健, 张永辉, 等. 启东市2001 ～2007 年女性乳腺癌患者的生存率分析[J/CD]. 中华乳腺病杂志:电子版,2011,5(1):12-17.
|
| [44] |
Brekelmans CT, Tilanus-Linthorst MM, Seynaeve C, et al.Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases[J]. Eur J Cancer,2007,43(5):867-876.
|
| [45] |
Graeser MK, Engel C, Rhiem K, et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers[J]. J Clin Oncol,2009,27(35):5887-5892.
|
| [46] |
Metcalfe K, Gershman S, Lynch HT, et al. Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers[J]. Br J Cancer,2011,104(9):1384-1392.
|
| [47] |
Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy,and lumpectomy plus irradiation for the treatment of invasive breast cancer[J]. N Engl J Med,2002,347(16):1233-1241.
|
| [48] |
Poggi MM, Danforth DN, Sciuto LC, et al. Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized Trial[J]. Cancer,2003,98(4):697-702.
|
| [49] |
van Dongen JA, Voogd AC, Fentiman IS, et al. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial[J]. J Natl Cancer Inst,2000,92(14):1143-1150.
|
| [50] |
Jeevan R, Cromwell DA, Trivella M, et al. Reoperation rates after breast conserving surgery for breast cancer among women in England: retrospective study of hospital episode statistics[J]. BMJ,2012,345: e4505.
|
| [51] |
Hwang ES, Lichtensztajn DY, Gomez SL, et al. Survival after lumpectomy and mastectomy for early stage invasive breast cancer: the effect of age and hormone receptor status[J].Cancer,2013,119(7):1402-1411.
|
| [52] |
Recht A, Solin LJ. Breast-conserving surgery and radiotherapy in early-stage breast cancer: the importance of local control[J]. Semin Radiat Oncol,2011,21(1):3-9.
|
| [53] |
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG),Peto R, Davies C, et al. Comparisons between different polychemotherapy regimens for early breast cancer: metaanalyses of long-term outcome among 100 000 women in 123 randomised trials[J]. Lancet,2012,379(9814):432-444.
|
| [54] |
De Vos FY, van Laarhoven HW, Laven JS, et al. Menopausal status and adjuvant hormonal therapy for breast cancer patients: a practical guideline[J]. Crit Rev Oncol Hematol, 2012, 84(2):252-260.
|
| [55] |
Del Mastro L, Levaggi A, Giraudi S, et al. Luteinising hormone releasing hormone agonists (LH-RHa) in premenopausal early breast cancer patients: current role and future perspectives[J].Cancer Treat Rev,2011,37(3):208-211.
|
| [56] |
Cuzick J, Sestak I, Bonanni B, et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data[J]. Lancet,2013,381(9880):1827-1834.
|
| [57] |
Sharma R, Hamilton A, Beith J, et al. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women[J]. Cochrane Database Syst Rev,2009,(4): CD004562.
|
| [58] |
Griggs JJ, Somerfield MR, Anderson H, et al. American Society of Clinical Oncology endorsement of the cancer care Ontario practice guideline on adjuvant ovarian ablation in the treatment of premenopausal women with early-stage invasive breast cancer[J]. J Clin Oncol,2011,29(29):3939-3942.
|
| [59] |
Robson ME, Chappuis PO, Satagopan J, et al. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment[J]. Breast Cancer Res,2004,6(1): R8-R17.
|
| [60] |
Pierce LJ, Levin AM, Rebbeck TR, et al. Ten-year multiinstitutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage Ⅰ/Ⅱbreast cancer[J]. J Clin Oncol,2006,24(16):2437-2443.
|
| [61] |
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG).Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials[J]. Lancet,2005,365(9472):1687-1717.
|
| [62] |
Gronwald J, Tung N, Foulkes WD, et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update[J]. Int J Cancer,2006,118(9):2281-2284.
|